Top Peptides Lyophilized Powder Tirzepatide Fitness and Weight Loss 10mg 20mg

Sales manager：Luna
WhatsApp：+852 93127825
Email：luna2206866@gmail.com

Pls input...

Tirzepatide has been shown to help lose weight in overweight patients. Phase 3 clinical trials are currently underway for weight loss in adults who are overweight, obese, or have weight-related health issues. Tirzepatide has received FDA Fast Track designation to speed up its FDA application for treating adults with obesity, or who are overweight with weight-related health conditions.
In the SURMOUNT-1 clinical trial, the average weight loss with tirzepatide after 72 weeks was 15% for the 5mg dose, 19.5% for the 10mg dose, and 20.9% for the 15mg dose.

tirzepatide is a once-weekly glucose-dependent-stimulating polypeptide (GIP, aka: gastric inhibitory polypeptide) receptor and glucagon-like peptide-1 (GLP-1) receptor dual agonist developed by scientists. ChemicalbookGIP and GLP-1 are both hormones secreted by the gut that promote secretion. tirzepatide combines the effects of two -promoting drugs into a single molecule and represents a new class of drugs for the treatment of type 2 diabetes.

How much weight can you lose in a week with tirzepatide?
Clinical trials have shown that study participants taking a weekly dose of semaglutide had an average reduction in body weight of 5-10 percent.

Description:

Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes. Tirzepatide (LY3298176) shows significantly better efficacy with regard to glucose control and weight loss than do Dulaglutide.

Tirzepatide, also known as LY 3298176, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide has a greater affinity to GIP receptors than to GLP-1 receptors, and this dual agonist behavior has been shown to produce greater reductions of hyperglycemia compared to a selective GLP-1 receptor agonist. Signaling studies reported that tirzepatide mimics the actions of natural GIP at the GIP receptor. Tirzepatide was approved for improving blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise.

Product picture:

• Description

  
  

   

    Product Detail  

   

  
  

  Sales manager:Smile

  whatsapp：+8617832002339  

  Email:smile@duole-tech.com

  Items	Specifications
  Product Name	Tirzepatide
  CAS No.	2023788-19-2
  Molecular Formula	C225H348N48O68
  Appearance	White Powder
  Packaging	10mg/vial, 10vials/box
  MOQ	10vials

  

  

  Tirzepatide has been shown to help lose weight in overweight patients. Phase 3 clinical trials are currently underway for weight loss in adults who are overweight, obese, or have weight-related health issues. Tirzepatide has received FDA Fast Track designation to speed up its FDA application for treating adults with obesity, or who are overweight with weight-related health conditions.
  In the SURMOUNT-1 clinical trial, the average weight loss with tirzepatide after 72 weeks was 15% for the 5mg dose, 19.5% for the 10mg dose, and 20.9% for the 15mg dose.

  tirzepatide is a once-weekly glucose-dependent-stimulating polypeptide (GIP, aka: gastric inhibitory polypeptide) receptor and glucagon-like peptide-1 (GLP-1) receptor dual agonist developed by scientists. ChemicalbookGIP and GLP-1 are both hormones secreted by the gut that promote secretion. tirzepatide combines the effects of two -promoting drugs into a single molecule and represents a new class of drugs for the treatment of type 2 diabetes.

  How much weight can you lose in a week with tirzepatide?
  Clinical trials have shown that study participants taking a weekly dose of semaglutide had an average reduction in body weight of 5-10 percent.

  Description:

  Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes. Tirzepatide (LY3298176) shows significantly better efficacy with regard to glucose control and weight loss than do Dulaglutide.

  Tirzepatide, also known as LY 3298176, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide has a greater affinity to GIP receptors than to GLP-1 receptors, and this dual agonist behavior has been shown to produce greater reductions of hyperglycemia compared to a selective GLP-1 receptor agonist. Signaling studies reported that tirzepatide mimics the actions of natural GIP at the GIP receptor. Tirzepatide was approved for improving blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise.

  
  

  Product picture:

  

  

  
  

  Before and after weight loss：

  

Product Name Tirzepatide
Purity ≥99%
Colour White Powder
CAS NO. 2023788-19-2
Molecular Formula C225H348N48O68
Molecular Weight 4813.527g/mol
Storage Store in cool and dry places, keep away from strong light.

Packing:

10mg/vial 10vials/box

15mg/vial 10vials/box

20mg/vial 10vials/box

30mg/vial 10vials/box

Real customer case：

——  About Us  ——